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Abstract
Hepatocellular carcinoma (HCC) is a major cause of 
morbidity and mortality worldwide. Chronic hepatitis 
C virus infection (HCV) is the most common cause of 
HCC in many European countries, Japan and Pakistan. 
Introduction of the new direct acting antivirals 
(DAAs) has revolutionized the management of HCV 
worldwide, with high rates of sustained virologic 
response in patients who could not have tolerated 
the previous interferon based treatments. However, 
recently there have been reports raising caution about 
the long term effects of DAAs, particularly a possible 
increased risk of HCC. Therefore this review explores 
the current molecular studies as well as clinical data 
that investigate the impact of DAAs on occurrence and 
recurrence of HCC. 
Key words: Hepatocellular carcinoma; Direct acting 
antivirals; Hepatitis C
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Our aim is to consolidate the existing literature 
as well as to identify whether there is a particular 
subset of the population in which this phenomenon 
was witnessed. The ground-breaking discovery of the 
new group of direct acting antiviral agents (DAAs) 
had led to a paradigm shift in the management of 
chronic hepatitis C (CHC). Wide variations have been 
observed in the studies assessing the long-term role 
of DAA based therapy on occurrence and recurrence 
of HCC. There is a need to differentiate weather the 
reported higher occurrence and recurrence rates are 
due to DAA or host and disease related factors and 
to identify subset of individuals particularly at risk. 
Also, future investigations should be directed towards 
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assessing the long-term effects of DAAs on group of 
patients that have not been studied thus far. Some 
important Centers in Europe and United States have 
been delaying antiviral treatment for 6 mo or more after 
the recent treatment for HCC. Hence, until more robust 
data is available, clinical practices should continue as 
per current guidelines in those patient groups who can 
benefit from DAA therapy with close surveillance of 
patients with advance fibrosis. 
Butt AS, Sharif F, Abid S. Impact of direct acting antivirals 
on occurrence and recurrence of hepatocellular carcinoma: 
Biologically plausible or an epiphenomenon? World J Hepatol 
2018; 10(2): 267-276  Available from: URL: http://www.
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INTRODUCTION
The ground breaking discovery of the new group 
of direct acting antiviral agents (DAAs) had led to a 
paradigm shift in the management of chronic hepatitis C 
(CHC) which is the most common cause of hepatocellular 
carcinoma (HCC) in Japan, Pakistan, United States and 
many European countries[1,2]. With annual incidence 
of HCC ranging from 1% to 7% in patients with HCV 
related cirrhosis, (HCC) is a leading cause of morbidity 
and the second most common cause of cancer related 
deaths worldwide[3,4]. Besides contribution of several 
host and viral factors in the pathogenesis of disease 
progression, achieving sustained virologic response 
(SVR) has been found as the single most important 
factor in reducing HCV associated HCC incidence[5]. 
The novel DAAs not only provided a potent, oral 
alternative to injectable interferons, but also had a 
shorter duration of treatment, better efficacy with over 
90% achievement of SVR and a more favorable side 
effect profile[6]. However, since 2016, concerns were 
raised regarding the effect of DAAs on progression to 
HCC[7]. In addition, their long-term benefits including 
impact on HCC have been questioned in the context 
of specific populations and subgroups which were not 
included in the landmark trials investigating DAA based 
therapy[3]. 
Therefore, this review aims to explore existing 
molecular studies as well as clinical observations in order 
to determine whether there is an association between 
the use of DAAs and the occurrence or recurrence of 
HCC among patients with HCV related liver disease. 
We also aim to evaluate whether there is a subset of 
the population in which this phenomenon has been 
observed. 
DAA AND CARCINOGENESIS: 
BIOLOGICALLY PLAUSIBLE OR NOT? 
The carcinogenesis of HCC is a chronic process with 
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several steps that may serve as potential targets for 
drug therapy. Unlike the hepatitis B virus, HCV is an RNA 
virus which is unable to integrate into the host genome 
and thus it is unlikely to have direct carcinogenic 
activity[8]. While the mechanism of carcinogenesis due 
to HCV is not completely understood, observations from 
transgenic mice models suggest that liver cancer occurs 
because of rapid hepatocyte turnover, dysregulation of 
apoptosis and generation of reactive oxygen species, 
arising in the setting of a chronic inflammatory state 
induced by HCV[9,10]. This indirect mechanism of cirrhosis 
driven carcinogenesis is supported by clinical data which 
shows a greater risk of HCC with chronic HCV infection 
and worsening liver fibrosis[8]. 
One of the mechanisms proposed regarding the 
risk of DAAs towards development of HCC is that DAAs 
downregulate interferon genes, disrupting the innate 
immunosurveillance of the body[8]. In the chronic phase 
of HCV, an estimated 1012 virions are produced per day 
by infected hepatocytes[11]. These trigger an immune 
response mediated primarily by natural killer (NK) cells 
which release cytokines such as interferon (IFN)-γ. IFNs 
upregulate interferon stimulated genes which have an 
anti-proliferative response by prolonging all phases of 
the cell cycle and decreasing viral replication. When 
HCV infection becomes persistent, NK cells become 
dysfunctional due to continuous antigenic stimulation by 
the high load of virions, resulting in impaired production of 
IFNs[12]. In mice models, it was observed that decreased 
levels of IFN-γ independently control tumorigenesis[13]. 
Thus the downregulation of these genes in IFN free 
therapy could contribute to development of HCC. 
Analysis of the peripheral blood mononuclear 
cells (PBMCs) of CHC patients treated with DAAs has 
shown that in comparison to healthy controls, these 
patients have attenuated activity of both NK cells 
and monocytes, reflected by a decreased level of 
inflammatory cytokines in patients who had achieved 
rapid virological response (RVR), i.e., undetectable HCV 
RNA at the end of 4 wk of DAA treatment[14]. Natural 
Killer cell group 2D (NKG2D) is an activating receptor 
of immune responses which has been studied in the 
context of HCV associated HCC. It has been found that 
in HCV patients treated with IFN free DAA therapy, an 
on treatment decrease in the expression of NKG2D 
correlated to the early occurrence and recurrence of 
clinically evident HCC within the 6-mo surveillance 
period following treatment[15]. 
With DAA based therapy, HCV RNA becomes 
undetectable in days to weeks, a much more rapid 
response than that observed with IFN based regimens. 
It is hypothesized that rapid eradication of HCV and 
subsequent abrupt resolution of the chronic inflammatory 
state disrupts the natural immune response of the body, 
possibly favoring the proliferation of neoplastic cells[16]. 
Since clinical studies have shown no difference among 
different DAA regimens and development of HCC, it is 
hypothesized that if this effect does exist then it would 
have to be a class effect of the DAAs[17,18]. 
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An experimental study analyzing the soluble inflam­
matory milieu from plasma cells of cirrhotic HCV 
patients found that HCV specific CD8+ T cells failed to 
recover from the baseline after DAA therapy. These cells 
play a role in HCC surveillance; therefore, their reduced 
activity in IFN free therapy could potentially affect 
development of HCC[19]. Furthermore, serum levels 
of microRNA (miRNA) 122 were found to be reduced 
in DAA treated HCV patients after achieving SVR[20]. 
Previous evidence shows that miRNA-122, which is the 
most abundant miRNA in the liver, functions as a tumor 
suppressor against HCC[21]. Thus it is hypothesized that 
decreased miRNA-122 in DAA treated patients could 
contribute to an increased risk of HCC recurrence[22]. 
Table 1 summarizes the possible factors that could lead 
to HCC in DAA treated HCV patients. 
DAA AND CARCINOGENESIS: REVIEW 
OF EXISTING EVIDENCE/DATA
Studies that observed increased incidence of HCC
While DAAs represented a major breakthrough in the 
treatment of CHC, one of the first reports questioning 
their long-term role in development of HCC came 
from Reig et al[8] in 2016. The authors retrospectively 
assessed a cohort of 58 patients who had a history 
of HCC secondary to HCV and had received different 
regimens of DAA based therapy. After a median follow 
up of 5.7 mo (range 0.4-14.6 mo), 16 out of their 58 
patients (27.6%) showed radiographic evidence of HCC. 
This study alerted the scientific community regarding 
the potential risks associated with use of DAAs and the 
authors called for a large­scale assessment to confirm 
their findings[8]. However, their method of statistical 
analysis was questioned by Camma and colleagues 
who felt that reporting the crude rate of recurrence was 
a weakness of the study because of the variation in 
time elapsed from treatment of HCC and starting DAAs 
(median 11.2 mo, range 1.2-87.7 mo)[23]. Cammà 
et al[23] used the data presented by Reig et al[24] to 
calculate the actuarial probability of HCC recurrence 
by plotting a Kaplan Meier curve. For their analysis, 
Cammà et al[23] used the time of HCC treatment as the 
initiation point, not the time of initiating DAA treatment 
as used by the original authors. With this method they 
found a much lower recurrence rate than that reported 
in the original study (7% and 13% at 6 and 12 mo 
respectively). 
Reig et al[24] later went on to present a follow up of 
their original cohort. In 2017, they reported that not 
only did they observe a higher recurrence rate of HCC 
among the DAA treated patients in their study; they 
also found a more aggressive pattern of recurrence 
in terms of tumor staging and subsequent treatment 
options. Renzulli et al[25] have also reported a rapid 
development of HCC following DAA treatment with a 
more aggressive pattern of microvascular invasion. The 
median duration between completion of DAA treatment 
and diagnosis of HCC in their patients was 82 d (range 
0-318). 
A retrospective study from Italy by Conti et al[18] 
reported HCC occurrence and recurrence rates of 
3.16% (95%CI: 1.45-5.90) and 28.81% (95%CI: 
17.76-42.07) respectively in a cohort of 344 CHC 
patients treated with different DAA regimens over a 
follow up of 24 wk. Approximately 69% of this patient 
population had HCV genotype 1 and 91% had achieved 
SVR. However, the lack of a control group makes the 
interpretation of these findings difficult. The authors 
attempted to account for this limitation by comparing 
their findings to those of a historic cohort of untreated 
cirrhotic patients at their center. They found an HCC 
occurrence rate of 3.2%, which was similar to their 
current study. Conti et al[18] have interpreted their 
results with caution. The authors claim that while 
DAA treatment of HCV does not seem to reduce the 
occurrence or recurrence of HCC, anitiviral treatment 
should be started as early as possible to prevent 
the development of cirrhosis and recommend active 
surveillance of all cirrhotic patients, during and after DAA 
therapy. 
In Portugal, Cardoso et al[26] found HCC incidence 
to be 7.4% within a one year follow up of cirrhotic 
patients that had achieved SVR after being treated 
with sofosbuvir and ledipasvir. These de novo HCC 
patients had been asymptomatic, and were detected 
on radiological screening. This emphasizes the 
recommendation of Conti et al[18] that there should be 
close monitoring of CHC patients for development of 
HCC, despite achieving SVR[25]. In a larger study from 
Belgium, it was found that there was no difference in 
the early occurrence of HCC among patients treated 
with DAAs with or without Peg-IFN. However, this study 
reported HCC recurrence of 15% in patients treated 
with DAAs alone as compared to 0% in those who 
received a combination of Peg-IFN and DAAs. This study 
had a predominantly HCV Genotype 1 population. In 
these patients the authors also noted that those who 
developed HCC had a higher baseline risk of HCC which 
is a potential confounder[27]. 
The most recent study on this research question is 
by Ida et al[28], published in October 2017. The study 
population comprised 100 patients from Japan with HCV 
genotype 1, treated with Daclastavir and Asunaprevir, 
who were followed for 15 mo. In this group, there were 
5 new cases and 12 recurrences of HCC. The authors 
Table 1  Possible factors contributing to hepatocellular carcinoma 
after hepatitis C virus eradication by direct acting antivirals
Down regulation of IFN genes
Presence of fibrosis
Sudden disruption of chronic inflammatory state
Impaired immune response by NK cells
T cell dysfunction
Decreased microRNA-122
IFN: Interferon; NK: Natural killer.
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progression to HCC among HCV infected patients[52]. 
In a large cohort of United States veterans with HCV, 
it was found that Hispanics were at greater risk of 
developing cirrhosis and HCC. Black race and Hispanic 
ethnicity have also been identified as independent 
predictors of treatment failure[53]. Indeed the first report 
raising caution about the possible association of DAAs 
with recurrence of HCC in an aggressive form did come 
from the Spanish cohort followed by Reig et al[8]. 
A systematic review and meta-analysis by Waziry 
et al[54] found that there was no difference in HCC 
occurrence and recurrence in CHC patients who received 
IFN based or DAA based regimens. However, the 
authors acknowledge that in their analysis they were 
unable to account for geographical variations. Due to 
the heterogeneity in the studies included in this meta-
analysis, the results should be interpreted with caution. 
In this meta-analysis most of the IFN based studies 
were from Japan whereas DAA based studies were from 
Europe. Hence, due to baseline difference in between 
two populations it’s hard to draw an accurate conclusion 
regarding occurrence or recurrence of HCC among 
DAA and IFN based therapy. Furthermore, they had 
to exclude several studies which had incomplete data 
regarding BCLC staging of HCC. 
In our literature review, the populations that we 
have found to be under-represented in terms of the 
current research question include Indians, Arabs and 
Africans. Additionally, while the 2 studies with the 
largest sample size are from the United States, these 
were limited to veterans only[33,34]. 
Genotype based variation of HCC in DAA treated patients
HCV genotype is an important consideration when 
considering progression to HCC. HCV genotype 3 is 
generally more aggressive and is associated with a 
higher risk of progression to cirrhosis and HCC[55]. To 
the best of our knowledge, the studies published so far 
suggesting a greater risk of HCC with DAA treatment 
have not identified a particular genotype of HCV that is 
significantly associated with this disease progression. 
However, as most of these reports are from Japan or 
European countries such as France and Italy, therefore 
the major disease burden studied has been of HCV 
genotype 1[35,37]. Table 4 lists the factors predisposing to 
development of HCC in DAA treated HCV patients.
WAY FORWARD
There is wide variation in the studies assessing the 
long-term role of DAA based therapy on occurrence 
and recurrence of HCC, both in terms of the baseline 
characteristics of study population and the different DAA 
regimens used. At present, most of the studies have 
been reported from regions where HCV genotype 1 is 
the most prevalent one[34,35]. Data is very limited from 
Asian populations where HCV Genotype 3 is the most 
common genotype. This is an important consideration 
as the different genotypes of HCV have a unique 
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have hypothesized that the high rate of HCC seen in 
this study could be related to a history of HCC, as these 
patients already had advanced fibrosis which is known 
to be implicated in the process of hepatocarcinogenesis. 
Table 2 summarizes the studies that report an increased 
incidence of HCC in DAA treated HCV patients. 
Studies that did not note any significant effect
In 2016 and 2017 there have been several other similar 
reports, fueling the debate regarding the role of DAAs 
in HCC. Two large retrospective cohort studies have 
been conducted in the United States to investigate this 
matter; one by Ioannou et al[33] with a sample size of 
62354 and the other by Kanwal et al[34] with 22500 
study participants. Both studies concluded that DAAs 
are not associated with a significant risk of HCC as 
compared to IFN based treatment. Ioannou et al[33] 
found that DAA induced SVR reduced the risk of HCC by 
71%. This effect was similar in groups who had received 
DAAs alone, DAAs in combination with IFN or IFN alone 
regimens, thus suggesting that achieving SVR could be 
the crucial factor for risk reduction of HCC, regardless 
of the therapeutic agents used[33]. Kanwal et al[34] found 
that while there was a relative risk reduction in HCC, the 
absolute risk of HCC still persisted in those patients who 
had DAA induced SVR. In both studies the risk of HCC 
was greater in cirrhotic patients. Additionally, Kanwal 
et al[34] found that diabetes mellitus, alcohol use and 
a higher Fib-4 Index for assessment of fibrosis were 
risk factors for occurrence of HCC in patients who had 
achieved SVR. However, both study populations were 
restricted to United States veterans and were mostly 
patients with HCV genotype 1. The specific population 
included in these studies might limit the generalization 
of their findings. 
The ANRS Collaborative Study Group assessed 
HCC recurrence rates among 3 French multicenter 
prospective cohorts who had received DAA based 
therapy after HCC curative treatment[35]. Their study 
included a diverse patient population with cirrhotics, 
non-cirrhotics and liver transplant recipients. They did 
not find any evidence that DAAs increases the risk of 
HCC recurrence. The strength of this study was that 
analysis of data from 3 distinct patient cohorts yielded 
fairly consistent results. Secondly, they included patients 
who had received curative therapy for HCC as opposed 
to non-curative therapies such as chemoembolization, 
leading to speculation that some of the earlier studies 
that had reported a higher recurrence rate might have 
included patients in whom the initial tumor staging 
was incorrect or was incompletely treated[35]. Table 3 
summarizes the studies that do not show an increased 
risk of HCC in DAA treated patients.
Geographical variation of incidence of HCC in DAA 
treated patients
Many of the studies investigating the link between DAAs 
and HCC have been from Japan or European countries. 
Racial differences are known to be implicated in the 
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response to DAA based therapy and are associated with 
a unique burden of HCC[56]. Beside male patients, group 
of individuals with prior history of HCC, cirrhosis and 
elevated AFP at baseline were found with greater risk of 
HCC if treated with DAAs. Currently, the phenomenon 
appears to be a class effect rather than an individual 
drug effect. Hence, focusing on these HCV patients 
and measuring the impact of DAAs on progression or 
development of HCC will help to estimate the more 
accurate risk. In certain studies higher rates of HCC 
recurrence was found. There is a need to differentiate 
whether the reported higher recurrence rate and more 
aggressive pattern of recurrence are due to DAA or host 
or disease related factors including presence of fibrosis, 
gaps in initial tumor staging and receiving non-curative 
therapies such as chemoembolization. Also, future 
investigations should be directed towards assessing the 
long-term effects of DAAs on these populations that 
have not been studied thus far[3]. In the meantime, a 
consensus recommendation seen in most of the studies 
at present is that even after achieving SVR, there should 
be close surveillance of patients with CHC especially 
with advance fibrosis and those who received a recent 
treatment for HCC in order to detect HCC at an early 
stage[18,19,26,32]. Some important Centers in Europe and 
United States have been delaying antiviral treatment for 
6 mo or more after recent treatment for HCC in these 
patients. Moreover, until more robust data is available 
to investigate the role of DAAs in HCV related HCC 
cases, clinical practice should continue as per current 
guidelines in those patient groups who can benefit from 
DAA therapy[51]. 
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